The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients

TY - JOUR

T1 - The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients

AU - Bremholm, Lasse

AU - Hornum, Mads

AU - Andersen, Ulrik B

AU - Hartmann, Bolette

AU - Holst, Jens Juul

AU - Jeppesen, Palle Bekker

N1 - Copyright © 2011 Elsevier B.V. All rights reserved.

PY - 2011/6/7

Y1 - 2011/6/7

N2 - Exogenous Glucagon-Like Peptide-2 (GLP-2) treatment improves intestinal wet weight absorption in short bowel syndrome (SBS) patients. In healthy subjects, administration of GLP-2 increases small intestinal blood flow. The aim of the study was to evaluate the effect of GLP-2 on mesenteric blood flow and dynamic changes in cardiac parameters in SBS patients with jejunostomy and varying length of remnant small intestine. Methods: 8 SBS patients with end-jejunostomy and less than 200 cm small intestine were given GLP-2, 1600. μg subcutaneously (SC), or isotonic saline in a double blinded manner. At 0, 30 and 60 min plasma GLP-2 was measured, and from 0 to 90 min, blood flow in the superior mesenteric artery (SMA) and the celiac artery (CA) was measured using Doppler ultrasound (US), and cardiovascular variables were measured by continuous impedance cardiography and finger plethysmography. Results: Plasma GLP-2 concentrations increased significantly in the GLP-2 group, whereas no changes were seen in the placebo group. Compared to baseline, GLP-2 SC elicited a 19.4% decrease (p < 0.01) in the resistance index (RI) and a 97.6% increase in time averaged maximal velocity (TAMV) in the SMA (P < 0.01). In the CA there were no significant changes in RI or TAMV in the GLP-2 or placebo group. Blood flow and length of remaining intestine were correlated (RI: y = 0.14 + 4.3, R = 0.83, p = 0.01 and TAMV: y = 1.21 + 21.3, R = 0.63, p = 0.09) GLP-2 non significantly increased cardiac output (CO), stroke volume (SV) and significantly increased heart rate (HR) compared to baseline. Conclusion: Subcutaneous GLP-2 increased SMA blood flow in end-jejunostomy SBS patients with less than 200 cm of remaining small intestine. The increase in blood flow correlated with the length of remaining intestine, suggesting that the increase is coupled to the metabolic actions of GLP-2 on the gut rather than effects on the vasculature.

AB - Exogenous Glucagon-Like Peptide-2 (GLP-2) treatment improves intestinal wet weight absorption in short bowel syndrome (SBS) patients. In healthy subjects, administration of GLP-2 increases small intestinal blood flow. The aim of the study was to evaluate the effect of GLP-2 on mesenteric blood flow and dynamic changes in cardiac parameters in SBS patients with jejunostomy and varying length of remnant small intestine. Methods: 8 SBS patients with end-jejunostomy and less than 200 cm small intestine were given GLP-2, 1600. μg subcutaneously (SC), or isotonic saline in a double blinded manner. At 0, 30 and 60 min plasma GLP-2 was measured, and from 0 to 90 min, blood flow in the superior mesenteric artery (SMA) and the celiac artery (CA) was measured using Doppler ultrasound (US), and cardiovascular variables were measured by continuous impedance cardiography and finger plethysmography. Results: Plasma GLP-2 concentrations increased significantly in the GLP-2 group, whereas no changes were seen in the placebo group. Compared to baseline, GLP-2 SC elicited a 19.4% decrease (p < 0.01) in the resistance index (RI) and a 97.6% increase in time averaged maximal velocity (TAMV) in the SMA (P < 0.01). In the CA there were no significant changes in RI or TAMV in the GLP-2 or placebo group. Blood flow and length of remaining intestine were correlated (RI: y = 0.14 + 4.3, R = 0.83, p = 0.01 and TAMV: y = 1.21 + 21.3, R = 0.63, p = 0.09) GLP-2 non significantly increased cardiac output (CO), stroke volume (SV) and significantly increased heart rate (HR) compared to baseline. Conclusion: Subcutaneous GLP-2 increased SMA blood flow in end-jejunostomy SBS patients with less than 200 cm of remaining small intestine. The increase in blood flow correlated with the length of remaining intestine, suggesting that the increase is coupled to the metabolic actions of GLP-2 on the gut rather than effects on the vasculature.

KW - Adult

KW - Aged

KW - Blood Pressure

KW - Cardiac Output

KW - Female

KW - Glucagon-Like Peptide 2

KW - Heart Rate

KW - Humans

KW - Male

KW - Mesenteric Arteries

KW - Middle Aged

KW - Regional Blood Flow

KW - Short Bowel Syndrome

KW - Young Adult

U2 - 10.1016/j.regpep.2011.03.003

DO - 10.1016/j.regpep.2011.03.003

M3 - Journal article

C2 - 21421014

SN - 0167-0115

VL - 168

SP - 32

EP - 38

JO - Regulatory Peptides

JF - Regulatory Peptides

IS - 1-3

ER -